Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

被引：0
|
作者：
Bernd Tischer
Renate Huber
Matthias Kraemer
Mario E. Lacouture
机构：
[1] Kantar Health,Dermatology Service, Department of Medicine
[2] Merck KGgA,undefined
[3] Memorial Sloan Kettering Cancer Center,undefined
来源：
Supportive Care in Cancer | 2017年 / 25卷
关键词：
Dermatologic adverse events; EGFR inhibitors; Health-related quality of life; Skin rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：651 / 660
页数：9
相关论文
共 50 条
  • [11] Patient selection in clinical trials of EGFR inhibitors
    Jänne, PA
    ANNALS OF ONCOLOGY, 2005, 16 : 16 - 16
  • [12] Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
    R. Califano
    N. Tariq
    S. Compton
    D. A. Fitzgerald
    C. A. Harwood
    R. Lal
    J. Lester
    J. McPhelim
    C. Mulatero
    S. Subramanian
    A. Thomas
    N. Thatcher
    M. Nicolson
    Drugs, 2015, 75 : 1335 - 1348
  • [13] Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
    Califano, R.
    Tariq, N.
    Compton, S.
    Fitzgerald, D. A.
    Harwood, C. A.
    Lal, R.
    Lester, J.
    McPhelim, J.
    Mulatero, C.
    Subramanian, S.
    Thomas, A.
    Thatcher, N.
    Nicolson, M.
    DRUGS, 2015, 75 (12) : 1335 - 1348
  • [14] Dermatologic adverse events during treatment with anti-PD1 inhibitors
    Benhuri, Benjamin
    Belum, V. R.
    Lacouture, Mario
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB116 - AB116
  • [15] Alzheimer's Disease and the Invisible Person: The Missing Patient Voice
    Leder, Garson
    Derse, Arthur R.
    AMERICAN JOURNAL OF BIOETHICS, 2022, 22 (07): : 87 - 90
  • [16] Is methadone maintenance treatment and indication missing from the medical record? A patient safety issue
    Walley, A. Y.
    Farrar, D.
    Cheng, D. M.
    Alford, D. P.
    Samet, J. H.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 : 334 - 335
  • [17] Is Methadone Maintenance Treatment and Indication Missing from the Medical Record? A Patient Safety Issue
    Walley, A. Y.
    SUBSTANCE ABUSE, 2009, 30 (01) : 97 - 98
  • [18] Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology
    Livingstone, E.
    Trarbach, T.
    Zimmer, L.
    Schuler, M.
    Schadendorf, D.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (1-2) : 39 - 44
  • [19] Dermatologic adverse events to chemotherapeutic agents, Part 1: cytotoxic agents, epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors
    Kyllo, Rachel L.
    Anadkat, Milan J.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2014, 33 (01) : 28 - 39
  • [20] Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events From Mechanism to Patient Care
    Manouchehri, Ali
    Kanu, Elishama
    Mauro, Michael J.
    Aday, Aaron W.
    Lindner, Jonathan R.
    Moslehi, Javid
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (02) : 301 - 308
12345